TABLE 3.

Predicted graft loss by HbA1c levels at 2–5 years post‐transplant, adjusted for Cox model covariates.

HbA1c level (% DCCT/mmol/mol IFCC)	Predicted graft loss (% & 95% Confidence interval)
	2 years	3 years	4 years	5 years
4.4%/24.6 mmol/mol	1.1% (0.4%–1.8%)	2.5% (1%–3.9%)	3.8% (1.5%–6%)	6.1% (2.5%–9.5%)
5.0%/31.1 mmol/mol	1.2% (0.5%–1.9%)	2.6% (1.1%–4.1%)	4% (1.7%–6.2%)	6.4% (2.8%–9.9%)
5.3%/34.4 mmol/mol	1.5% (0.6%–2.3%)	3.2% (1.4%–4.9%)	4.9% (2.2%–7.5%)	7.8% (3.5%–11.8%)
5.7%/38.8 mmol/mol	2% (0.8%–3.2%)	4.3% (1.9%–6.7%)	6.6% (2.9%–10.1%)	10.5% (4.7%–15.9%)
6.5%/47.5 mmol/mol	2.7% (1.1%–4.3%)	5.7% (2.4%–9%)	8.7% (3.7%–13.4%)	13.8% (6%–20.9%)
7.0%/53.0 mmol/mol	2.9% (1.1%–4.6%)	6.2% (2.6%–9.6%)	9.4% (4%–14.5%)	14.8% (6.5%–22.4%)
8.0%/63.9 mmol/mol	3.4% (1.3%–5.4%)	7.1% (2.9%–11.2%)	10.8% (4.5%–16.7%)	17% (7.3%–25.7%)

Cox model adjusted for: donor age, donor BMI, donor cause of death, donor type, pancreas preservation time, HLA mismatch, CMV match, duct management strategy, steroid maintenance, donor ethnicity, recipient age, recipient BMI, cPRA, recipient diabetes type, prior pancreas transplant, dialysis at transplant, treatment for pancreas rejection in the first year, treatment for kidney rejection in the first year, C-peptide at one-year follow-up, HbA1c at one-year follow-up, and eGFR at one-year follow-up.